DPP-4 Inhibitor

14 Drugs classified under this drug class

Biguanide, DPP-4 Inhibitor. Vildagliptin 50 mg, Metformin Hydrochloride 500, 850, 1000 mg.
F.C. TABS: 60 x Vildagliptin 50 mg/
Metformin 500 mg; 60 x
Vildagliptin 50 mg/Metformin 850 mg;
Vildagliptin 50 mg/Metformin 1,000 mg.
Based on the pt. current dose of
Metformin, tmt. may be init. at either
50 mg /500 mg or 50 mg/850 mg or 50
mg/1000 mg tab. strength BID, one
tab. in the morning and evening. Pts
already receiving metformin +
vildagliptin from separate tabs: switch
to the equivalent combined tab. Daily
doses >100 mg of vildagliptin are not
recommend. See lit.
Tmt. type 2 diabetes mellitus in adult pts.
insuffic. controlled with max. tolerat.
dose Metformin alone or already treat.
with vildaliptin and Metformin as
separate tabs. In comb. with a
sulfonylurea as an adjunct to diet and
exercise in adult pts. inadeq. controlled
with metformin and a sulfonylurea. In
triple comb. ther. with insulin as an
adjunct to diet and exercise to improve
glycaemic control in adult pts.when
insulin at a stable dose and Metformin
alone do not provide adeq. glycaemic
control.
C/I: Hypersens., Diab. ketoacid., diabet.
pre-coma. Ren. fail. ,ren,dysfunc, (CrCl<
60 ml/min) dehydr., sev. infec., shock.
Intravasc. admin. of iod. contrast ag. Acute/ chron. dis. which may cause
tissue hypox., (e.g: Card. fail.). Resp. fail.,
recent MI, Hep. impair. Acute alcohol
intox., alcoholism. Lact.

DPP-4 Inhibitor. Vildagliptin 50 mg.
TABS: 7, 14, 28, 56.
Dosage must be indivi. ajust. for each pt.
Monotherpy: 50 mg x1 dly in the
morning or 50 mg x 2 dly (morn.,even.).
In combin. with other antidiabetics:
see lit. Max 100 mg dly, with/out food.
As adjunct to diet, exercise in type 2
diabetes mellitus: As monother. if diet,
exercise insuffic., or in combinat. with
metformin or sulfonylurea if tmt. with
these offers insuffic. control blood
glucose. As triple ther. in combinat. with
a sulphonylurea and metformin when
diet, exercise plus dual therapy do not
provide adequate glycaemic control.
Comb. use with insulin (with/ without
metformin) when diet, exercise plus a
stable dose of insulin do not provide
adequate glycaemic control. As an
adjunct to diet and exercise in pts. with
type 2 diabetes mellitus.In comb. with a
thiazolidinedione, in pts. with insuffic.
glycaemic control and for whom the use
of a thiazolidinedione is appropriate.
C/I: Hypesens.

DPP-4 Inhibitor, SGLT2 Inhibitor. Empagliflozin 10, 25 mg, Linagliptin 5 mg.
F.C.TABS.: 30. The recomm. dose of this drug is 10 mg empagliflozin/5 mg linagliptin once dly. in the morn., taken with/ without food. In pts. tolerat. this formul., the dose may be incr. to 25 mg empagliflozin/5 mg linagliptin once dly. See lit.
Indic. as an adjunct to diet and exercise to improve glycem. control in adults with type 2 diab. mell. when tmt. with both empagliflozin and linagliptin is approp..
C/I: Sev. ren. impair., end-stage renal dis., or dialysis. Hist. of hypersens. reaction to linagliptin, such as anaphylax., angioedema, exfoliative skin condit., urticaria, or bronch. hyperreactivity. Hist. of serious hypersens. reaction to empagliflozin.

Biguanide, DPP-4 Inhibitor. Metformin Hydrochloride 500 mg, Sitagliptin 50 mg.
TABS: 56. 2 x dly with meals. Graduate
dosage to avoid GI side effects. Max.
dly dose: 100 mg sitagliptin/2,000 mg
metformin HCl.
Adjunct to diet/excercise to improve
glycemic control in type 2 diabetes
mellitus, when tmt. with both sitagliptin
and metformin approp. Not to be used in
type 1 diabetes or tmt. diabet.
ketoacidos. Not studied in history
pancreatit. See lit.
C/I: Ren. dis./dysfunct.; acute/chron.
metabol. acidos. (incl. diabet. acidos.)
with/out coma, hypersens., discont.
when undergoing radiolog. studies
involving IV admin. or iodinated contrast
materials.

Biguanide, DPP-4 Inhibitor. Metformin Hydrochloride 850 mg, Sitagliptin 50 mg.
TABS: 56. 2 x dly with meals. Graduate
dosage to avoid GI side effects. Max.
dly dose: 100 mg sitagliptin/2,000 mg
metformin HCl.
Adjunct to diet/excercise to improve
glycemic control in type 2 diabetes
mellitus, when tmt. with both sitagliptin
and metformin approp. Not to be used in
type 1 diabetes or tmt. diabet.
ketoacidos. Not studied in history
pancreatit. See lit.
C/I: Ren. dis./dysfunct.; acute/chron.
metabol. acidos. (incl. diabet. acidos.)
with/out coma, hypersens., discont.
when undergoing radiolog. studies
involving IV admin. or iodinated contrast
materials.

Biguanide, DPP-4 Inhibitor. Metformin Hydrochloride 1000 mg, 500 mg, Sitagliptin (as Phosphate Salt) 100 mg, 50 mg.
TABS: 30, 60. Once dly with meals, pref. in
the evening. Max. dly dose: 100 mg sitagliptin/2,000 mg metformin HCl.
Adjunct to diet/exercise to improve
glycemic control in adults with type 2
diabetes mellitus, when tmt. with both
sitagliptin and metformin ext. release is
approp.
C/I: Ren. impairm., acute/chron.
metabol. acidos. (incl. diabet.
ketoacidos.), hypersens. to metformin,
history of hypersens. reaction to the
product or sitagliptin.